Japan’s Medical Insurance Agency Approves NHI Listing For Pfizer’s Macugen, Novartis’ Simulect, Merck Serono's Erbitux Among Others
This article was originally published in PharmAsia News
Japan's Central Social Insurance Medical Council (Chuikyo) approved Aug. 27 11 drugs to be NHI listed. The drugs priced based on similar drugs include Astellas's Irribow (ramosetron) to treat male irritable bowel syndrome, Pfizer's Macugen (pegaptanib) to treat age-related macular degeneration, Taiho Pharmaceutical's Zosyn (piperacillin/tazobactam), Schering Plough's Nasonex (mometasone furoate), and Galderma's Differin Gel (adapalene). The drugs priced based on a cost accounting system include Pfizer's Mycobutin (rifabutin), Merck Serono's colon cancer drug Erbitux (cetuximab) and Genzyme Japan's Thymoglobulin to treat acute rejection of transplants. Additional drugs to be listed include Astellas' Prograf (tacrolimus) and Novartis' Simulect Pediatric (basiliximab). (Click here for more - Japanese language
You may also be interested in...
Bridges Consumer Healthcare launched by former Sanofi executives gets its first brand by acquiring North American rights to Pfizer’s ThermaCare HeatWraps brand. Pfizer divested the brand so European regulators would give antitrust clearance to its consumer JV with GSK.
Rosa DeLauro prevails over fellow Democrats Debbie Wasserman Schultz and Marcy Kaptur for Appropriations chair. Frank Pallone gets unanimous support from Democrats to continue as Energy and Commerce chair.
The US Medicare agency is offering more lower-cost alternative sites for 2021 surgical procedures to be covered under its OPPS and ASC final rule.